Primary liver cancer
Conditions
Interventions
Sponsors
Chongqing Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Those who meet the above-mentioned Western medicine diagnostic criteria for primary liver cancer and TCM syndrome differentiation; 2. Patients with CNLC stage Ib-IIIa; 3. Have not received any treatment for HCC, such as surgical resection, ablation, TACE, etc.; 4. Those who have good compliance, take medicine on time, review at the specified time, and have a cheerful personality; 5. Patients between the ages of 18 and 70; 6. The choice of embolic agent is ultra-liquefied lipiodol, and the dosage is determined according to the size of the tumor. The maximum amount of one administration does not exceed 20ml.
Exclusion criteria
Exclusion criteria: 1. Combined with other systemic malignant tumors at the same time; 2. Serious adverse drug reactions; 3. Combined with severe complications of advanced decompensation of tumor and liver cirrhosis, such as upper gastrointestinal bleeding, hepatorenal syndrome, hepatic encephalopathy, etc.; 4. Those who are mentally ill or unable to cooperate; 5. There are absolute contraindications to TACE treatment; 6. Patients with severe heart disease, or kidney, brain, lung and hematopoietic system diseases; 7. The researcher believes that it is not suitable to participate in this clinical researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood routine;Liver function;C-reactive protein;Alpha-fetoprotein;IL-12;Basic fibroblast growth factor;Vascular endothelial growth factor;MMP-9; | — |
Countries
China
Contacts
Public ContactHuang Yi
Chongqing Traditional Chinese Medicine Hospital
Outcome results
None listed